Who this is for
If you have been told your lung cancer has an EGFR mutation and are trying to understand the standard first treatment — and what outcomes to expect — this is for you.
How common is this — and who gets it
EGFR mutations are found in:
• 10–15% of lung cancers in Western populations
• 30–50% in Asian populations
• More commonly in people who have never smoked
• More commonly in women
This matters because when this mutation is present, treatment changes completely.
The standard first treatment: osimertinib
Treatment for EGFR-mutated lung cancer is usually targeted therapy, not chemotherapy.
The current standard approach for most patients has been osimertinib, a third-generation EGFR inhibitor taken as a tablet.
In the FLAURA trial:
• Median progression-free survival: 18.9 months
• Median overall survival: 38.6 months
• Hazard ratio for death: 0.80
This represents a meaningful improvement compared to earlier EGFR treatments.
In practical terms, many patients are able to live several years with good disease control.
What treatment feels like
Osimertinib is generally better tolerated than chemotherapy.
Common side effects include:
• Mild skin rash
• Diarrhoea
• Fatigue
For most patients, these are manageable and allow continuation of daily activities.
Why timing matters
One of the most important decisions is when to start treatment.
If a patient is clinically stable, it is often better to wait for molecular testing results before starting therapy.
Starting chemotherapy too early can mean missing the opportunity to begin targeted therapy first.
In modern lung cancer care, the first treatment choice is often the most important decision.
What happens later
Over time, resistance develops. This is expected biology.
When this happens:
• Repeat biopsy or blood testing may be performed
• New resistance pathways may be identified
• Treatment is adjusted accordingly
This is where careful interpretation becomes essential.
Why this matters
For patients in Melbourne, and for those in Sri Lanka, the Philippines, Indonesia, and the Maldives seeking coordinated second opinions, EGFR-mutated lung cancer is one of the clearest examples of how understanding cancer biology changes outcomes.
The key is not just starting treatment quickly — but starting the right treatment first.
Key Takeaway
• EGFR mutations are common in Asian populations and in non-smokers, and they change treatment decisions completely.
• Osimertinib alone provides median survival approaching 3+ years, with many patients doing well beyond this.
• The most important step is accurate testing and correct first-line treatment selection.
Key Evidence (AMA style)
1. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non–small-cell lung cancer: a systematic review. Am J Cancer Res. 2015;5(9):2892-2911.
2. Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated EGFR-mutated NSCLC. N Engl J Med. 2020;382(1):41-50. doi:10.1056/NEJMoa1913612
3. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated NSCLC. N Engl J Med. 2018;378(2):113-125. doi:10.1056/NEJMoa1713137